Objective
Injectable bulking agents have been attempted to treat and manage stress urinary incontinence since the 1990's. But their application has been limited by efficacy, durability, biocompatibility, usability and other issues. Lack of a single, reproducible response from one agent has led to the adoption of several such materials. However, none of those materials can be used as a scaffold for tissue regeneration, they are mostly temporary tissue fillers. Once they degrade, the effectivity is diminished, typically within 6-8 months only. A permanent bulking agent was not successful as it often causes immunological adverse events (such as foreign body granulomas) that limit safety and efficacy. Between 1995-2011 a bovine crosslinked collagen product – Contigen® was used successfully to treat PMSI in dogs, however its production was stopped in 2011. CellFoam™ is a biomaterial scaffold augmentation agent that stimulates the body own cells to build de-novo tissue in place of the biomaterial. Thus, when degraded, a long-term tissue augmentation effect is maintained by urethral remodelling. As such continence is resolved.
The overarching objective of the present feasibility study is to mitigate risks related to subsequent phases of the CellFoam™ innovation project, i.e. the risks associated with the planned industrialization, the commercialization of the solution and post-project exploitation of the results.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- agricultural sciencesanimal and dairy sciencedomestic animals
- medical and health sciencesmedical biotechnologytissue engineering
- social sciencespolitical sciencespolitical transitionsrevolutions
- engineering and technologyindustrial biotechnologybiomaterials
Programme(s)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
30815 KIBUTZ NAHSHOLIM
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.